Candel Therapeutics, Inc. (CADL) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
01M2M3M4M6M7M8M9MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Margin (%)

Operating Expenses

Research And Development ExpensesGeneral And Administrative ExpensesOther Expenses
02M5M8M10M12M15M18M20MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EBITDA

EBITDA
-20M-16M-12M-9M-5M-1M2M6M10MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EPS

EPSEPS Diluted
000001111Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue Variation (%)

Revenue Variation
-200-175-150-125-100-74-49-241Q1 2025

Income Variation (%)

Gross Profit VariationOperating Income Variation
0612192531384450Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue YoY Variation (%)

Revenue YoY Variation
-60-52-45-37-30-22-14-71Q4 2024

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY Variation
0815223038455260Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Price-to-Earning Ratio

P/E Ratio
-20-17-13-10-6-3047Q3 2024Q4 2024Q1 2025Q2 2025

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
04M8M11M15M19M22M26M30MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
012344567Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
025M50M75M100M125M150M175M200MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
025M50M75M100M125M150M175M200MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025
🏦 Balance Sheet
📈 Key Metrics